Hyperkalemia consequences on the probability of interrupting or lowering renin-angiotensin-aldosterone system inhibitors and risk of hospitalization in patients with chronic cardiovascular conditions
Event: Heart Failure 2024
Topic: Angiotensin-Renin-Bradykinin System
Session: Treating heart failure with diabetes and renal disease
Influence of multi-morbidity in the effectiveness of transitional-care heart failure programmes: a population-based study with longitudinal real-world data in 77,554 patients.
Event: Heart Failure 2023
Topic: Multidisciplinary Interventions
Session: Chronic heart failure - rehabilitation
Management of renin-angiotensin-aldosterone system inhibitors in patients with chronic cardiovascular conditions and its association with clinical outcomes
Event: ESC Congress 2022
Topic: Epidemiology, Prognosis, Outcome
Session: Chronic heart failure - Epidemiology, prognosis, outcome 1
Implications of hyperkalemia in the management of renin-angiotensin-aldosterone system inhibitors in patients with chronic cardiovascular conditions and its association with clinical outcomes
Event: Heart Failure 2022
Topic: Epidemiology, Prognosis, Outcome
Session: Heart Failure ePosters - focus on Chronic Heart Failure 9
36,269 patients with chronic cardiovascular, metabolic and renal conditions: impact on clinical outcomes, medical resource use and health-related costs of deranged serum potassium levels
Event: ESC Congress 2020
Topic: Epidemiology, Prognosis, Outcome
Session: Changing Epidemiology of Heart Failure
Impact on clinical events and healthcare costs of adding telemedicine to multidisciplinary care of patients with heart failure and mid-range or preserved LVEF: a randomised controlled trial
Event: ESC Congress 2017
Topic: AHF - Non pharmacological treatment
Session: Acute Heart Failure (AHF)
